Follow-on biologicals and extrapolation in Brazil

Posted 16/03/2018

Researchers from Brazil discuss the country’s approach to follow-on biologicals and extrapolation of indications in the country [1].

Insulin glargine biosimilar gains South Korean... Biosimilars/News | Posted 16/03/2018
Biosimilar policies around the globe Biosimilars/Research | Posted 16/03/2018
Michigan latest state to pass biosimilars subst... Policies & Legislation | Posted 16/03/2018
Barriers to HIV generics in the US Generics/Research | Posted 16/03/2018
US drug contracting system is ‘rigged’ against... Biosimilars/General | Posted 16/03/2018
Lupin launches generic memantine XR capsules in... Generics/News | Posted 16/03/2018
ASCO issues position statement on biosimilars i... Biosimilars/Research | Posted 09/03/2018
Bioequivalence of brand-name and two generic ta... Generics/Research | Posted 09/03/2018
Trastuzumab biosimilar launched in South Korea Biosimilars/News | Posted 09/03/2018
Use and cost of biologicals for cancer treatmen... Biosimilars/Research | Posted 09/03/2018
Ireland’s National Biosimilar Medicines Policy... Policies & Legislation | Posted 09/03/2018
Cadila and Kalbe advancing biosimilar ambitions Biosimilars/General | Posted 09/03/2018
Joint 24th Medicines for Europe and 21st IGBA A... Conferences | Posted 09/03/2018
Kissei/JCR’s darbepoetin alfa biosimilar shows... Biosimilars/Research | Posted 02/03/2018
US government tries to address the increasing c... Generics/General | Posted 02/03/2018
Obstacles to biosimilars uptake in the US Reports | Posted 02/03/2018
Mylan and Revance team up for botox biosimilar Pharma News | Posted 02/03/2018
Adverse outcomes for elderly using generic vers... Generics/Research | Posted 02/03/2018
EC approval for trastuzumab biosimilar Herzuma Biosimilars/News | Posted 02/03/2018
Pharmacy-mediated substitution: the global poli... Biosimilars/Research | Posted 02/03/2018
Generics versus biosimilars: pricing and usage-... Biosimilars/Research | Posted 23/02/2018
Biosimilars of denosumab Biosimilars/General | Posted 23/02/2018
Canada’s generics industry to cut prices by up... Generics/General | Posted 23/02/2018
Persistence with generic imatinib in CML patients Generics/Research | Posted 23/02/2018
Etanercept switching study investigates non-man... Biosimilars/Research | Posted 23/02/2018
EBE reveals Europe’s biosimilar pricing and rei... Biosimilars/Research | Posted 15/02/2018
EMA approval for biosimilar insulin glargine Se... Biosimilars/News | Posted 15/02/2018
Quality and clinical performance of biopharmace... Biosimilars/Research | Posted 15/02/2018
Building confidence in biosimilars Reports | Posted 15/02/2018
Europe calls for more drugs repurposing Generics/General | Posted 15/02/2018
Efficacy and safety of generic imatinib after s... Generics/Research | Posted 15/02/2018
Zarxio reveals all: the US biosimilars market Biosimilars/Research | Posted 09/02/2018
Comments on TGA’s modified approach to naming b... Policies & Legislation | Posted 09/02/2018
Quebec adds biosimilar etanercept Erelzi to pub... Biosimilars/General | Posted 09/02/2018
Approval rating and opinion on generic drugs in... Generics/Research | Posted 09/02/2018
Structure-function relationship between disulfi... Biosimilars/Research | Posted 09/02/2018
Denosumab biosimilar being developed in Australia Biosimilars/News | Posted 09/02/2018
Medicines for Europe 14th Legal Affairs Conference Conferences | Posted 09/02/2018
Medicines for Europe 16th Biosimilar Medicines... Conferences | Posted 09/02/2018
The biosimilar landscape in Italy revealed Biosimilars/Research | Posted 02/02/2018


FDA approves 40 mg follow-on version of glatiramer acetate Posted 09/03/2018

Sandoz, the generics division of Novartis, announced on 13 February 2018 the...


Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 05/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015